3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Osteosarcoma
2
Neoplasm Metastasis
2
Gliosarcoma
2
Glioblastoma
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Oligodendroglioma
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
pembrolizumab
4
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
tislelizumab
2
aflibercept
2
Surveys and Questionnaires
2
Radiotherapy
2
Gene Expression Profiling
2
Fentanyl
2
Docetaxel
2
Diet Therapy
2
Blood Specimen Collection
2
Biopsy
2
trastuzumab deruxtecan
1
toripalimab
1
spartalizumab
1
sargramostim
1
rucaparib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
milademetan
1
entinostat
1
durvalumab
1
ciforadenant
1
ceralasertib
1
cemiplimab
1
avelumab
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
Colony-Stimulating Factors
×
Sarcoma
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled